{"id":"ifenprodil","rwe":[{"pmid":"41811034","year":"2026","title":"Discovery and Evaluation of N-Arylindole-Based GluN2B-NMDAR Antagonists with Reduced Cardiotoxicity for the Treatment of Ischemic Stroke.","finding":"","journal":"Journal of medicinal chemistry","studyType":"Clinical Study"},{"pmid":"41777141","year":"2026","title":"[Differential effects of GluN2A and GluN2B subunits in the medial prefrontal cortex on chronic pain and anxiety/depressive-like behaviors].","finding":"","journal":"Sheng li xue bao : [Acta physiologica Sinica]","studyType":"Clinical Study"},{"pmid":"41764828","year":"2026","title":"Development of a MS binding assay to analyze the interactions of drugs with the ifenprodil binding site of NMDA receptors with GluN2B subunit.","finding":"","journal":"Journal of pharmaceutical and biomedical analysis","studyType":"Clinical Study"},{"pmid":"41615455","year":"2026","title":"Mice carrying a GluN2B protein-truncating variant have altered NMDA receptor subunit composition and their behavior recapitulates patient phenotypes.","finding":"","journal":"Cellular and molecular life sciences : CMLS","studyType":"Clinical Study"},{"pmid":"41469232","year":"2026","title":"Stereoselective Synthesis of Conformationally Restricted γ- and β-Amino Alcohols as GluN2B Subtype-Selective NMDA Receptor Antagonists.","finding":"","journal":"Journal of medicinal chemistry","studyType":"Clinical Study"}],"tags":[{"label":"ifenprodil","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Sigma non-opioid intracellular receptor 1","category":"target"},{"label":"SIGMAR1","category":"gene"},{"label":"GRIN1","category":"gene"},{"label":"GRIN2B","category":"gene"},{"label":"C04AX28","category":"atc"},{"label":"Active","category":"status"},{"label":"Adrenergic Agents","category":"pharmacology"},{"label":"Adrenergic Antagonists","category":"pharmacology"},{"label":"Adrenergic alpha-Antagonists","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Excitatory Amino Acid Antagonists","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Vasodilator Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["ifenprodil","ifenprodil tartrate"],"offLabel":[],"synonyms":["ifenprodil","ifenprodil tartrate"],"timeline":[],"aiSummary":"IFENPRODIL is a small molecule drug class ifenprodil that targets the Sigma non-opioid intracellular receptor 1. It is currently owned by an unknown entity, and its original development is attributed to an unspecified company. IFENPRODIL's commercial status, including FDA approval and generic availability, is unknown. As a result, its approved indications and off-patent status are also unclear. Key safety considerations include its half-life of 4.32 hours.","approvals":[],"ecosystem":[],"mechanism":{"target":"Glutamate receptor ionotropic, NMDA 2A, Glutamate receptor ionotropic, NMDA 2B, Glutamate receptor ionotropic, NMDA 2C","targets":[{"gene":"SIGMAR1","source":"DrugCentral","target":"Sigma non-opioid intracellular receptor 1","protein":"Sigma non-opioid intracellular receptor 1"},{"gene":"GRIN1","source":"DrugCentral","target":"Glutamate NMDA receptor; GRIN1/GRIN2B","protein":"Glutamate receptor ionotropic, NMDA 1"},{"gene":"GRIN2B","source":"DrugCentral","target":"Glutamate NMDA receptor; GRIN1/GRIN2B","protein":"Glutamate receptor ionotropic, NMDA 2B"},{"gene":"KCNH2","source":"DrugCentral","target":"Potassium voltage-gated channel subfamily H member 2","protein":"Potassium voltage-gated channel subfamily H member 2"},{"gene":"HRH1","source":"DrugCentral","target":"Histamine H1 receptor","protein":"Histamine H1 receptor"},{"gene":"GRIN2C","source":"DrugCentral","target":"Glutamate receptor ionotropic, NMDA 2C","protein":"Glutamate receptor ionotropic, NMDA 2C"},{"gene":"GRIN2A","source":"DrugCentral","target":"Glutamate receptor ionotropic, NMDA 2A","protein":"Glutamate receptor ionotropic, NMDA 2A"},{"gene":"GRIN2D","source":"DrugCentral","target":"Glutamate receptor ionotropic, NMDA 2D","protein":"Glutamate receptor ionotropic, NMDA 2D"}],"modality":"Small Molecule","drugClass":"ifenprodil","explanation":"Think of it like a key fitting into a lock. IFENPRODIL is the key that blocks the Sigma receptor, which can help reduce pain and other symptoms. This blocking action helps to modulate the receptor's activity, leading to therapeutic effects.","oneSentence":"IFENPRODIL works by selectively blocking the Sigma non-opioid intracellular receptor 1.","technicalDetail":"IFENPRODIL acts as a selective antagonist of the Sigma non-opioid intracellular receptor 1 (σ1R), a subtype of the sigma receptor family, which plays a role in modulating various physiological processes, including pain perception and neurotransmitter release."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1419","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=IFENPRODIL","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=IFENPRODIL","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:00:59.734955","biosimilars":[],"competitors":[{"drugName":"phenoxybenzamine","drugSlug":"phenoxybenzamine","fdaApproval":"1953-01-26","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"ifenprodil","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"phenoxybenzamine","brandName":"phenoxybenzamine","genericName":"phenoxybenzamine","approvalYear":"1953","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06330077","phase":"PHASE2","title":"Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-03","conditions":["Multiple Sclerosis","Remitting Relapsing Multiple Sclerosis"],"enrollment":60,"completionDate":"2027-06"},{"nctId":"NCT04318704","phase":"PHASE2","title":"Efficacy, Safety and Tolerability of NP-120 on Idiopathic Pulmonary Fibrosis and Its Associated Cough","status":"COMPLETED","sponsor":"Algernon Pharmaceuticals","startDate":"2020-07-29","conditions":["Idiopathic Pulmonary Fibrosis"],"enrollment":20,"completionDate":"2022-05-10"},{"nctId":"NCT04382924","phase":"PHASE2,PHASE3","title":"Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease","status":"COMPLETED","sponsor":"Algernon Pharmaceuticals","startDate":"2020-08-05","conditions":["COVID"],"enrollment":168,"completionDate":"2021-01-26"},{"nctId":"NCT01896388","phase":"PHASE1,PHASE2","title":"Ifenprodil Tartrate Treatment of Adolescents With Post-traumatic Stress Disorder: a Double-blind, Placebo-controlled Trial","status":"COMPLETED","sponsor":"Chiba University","startDate":"2014-01-21","conditions":["Posttraumatic Stress Disorders"],"enrollment":10,"completionDate":"2019-03"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NDDF":"005790","UNII":"R8OE3P6O5S","CHEBI":"CHEBI:31688","INN_ID":"3236","RXNORM":"27403","UMLSCUI":"C0063340","ChEMBL_ID":"CHEMBL305187","KEGG_DRUG":"D01445","DRUGBANK_ID":"DB08954","PDB_CHEM_ID":" QEL","PUBCHEM_CID":"3689","SNOMEDCT_US":"16291000122106","IUPHAR_LIGAND_ID":"5472","SECONDARY_CAS_RN":"23210-58-4","MESH_SUPPLEMENTAL_RECORD_UI":"C010739"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"4.32 hours","clearance":"64.57 mL/min/kg","volumeOfDistribution":"18.99 L/kg"},"publicationCount":1128,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"C04AX28","allCodes":["C04AX28"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 26","pmid":"41811034","title":"Discovery and Evaluation of N-Arylindole-Based GluN2B-NMDAR Antagonists with Reduced Cardiotoxicity for the Treatment of Ischemic Stroke.","journal":"Journal of medicinal chemistry"},{"date":"2026 Feb 25","pmid":"41777141","title":"[Differential effects of GluN2A and GluN2B subunits in the medial prefrontal cortex on chronic pain and anxiety/depressive-like behaviors].","journal":"Sheng li xue bao : [Acta physiologica Sinica]"},{"date":"2026 Jul 15","pmid":"41764828","title":"Development of a MS binding assay to analyze the interactions of drugs with the ifenprodil binding site of NMDA receptors with GluN2B subunit.","journal":"Journal of pharmaceutical and biomedical analysis"},{"date":"2026 Jan 30","pmid":"41615455","title":"Mice carrying a GluN2B protein-truncating variant have altered NMDA receptor subunit composition and their behavior recapitulates patient phenotypes.","journal":"Cellular and molecular life sciences : CMLS"},{"date":"2026 Jan 22","pmid":"41469232","title":"Stereoselective Synthesis of Conformationally Restricted γ- and β-Amino Alcohols as GluN2B Subtype-Selective NMDA Receptor Antagonists.","journal":"Journal of medicinal chemistry"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"IFENPRODIL","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}